Lifeward AI Stock Analysis
Want to see LFWD full AI Analyst Report?
Lifeward (LFWD) AI Stock Analysis
Lifeward
(NASDAQ:LFWD)
LFWD scores low primarily due to very weak financial performance (sharp net losses, negative cash flow, and declining TTM revenue) and poor technicals (price well below all key moving averages with bearish momentum). Valuation offers limited support because losses drive a negative P/E and there is no dividend yield. Corporate events are slightly supportive (new CFO and strategic messaging) but are not large enough to change the overall risk-heavy picture.
Lifeward (LFWD) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $4.75M
- Dividend Yield
- ―
- Average Volume (3M)
- 12.18K
- Price to Earnings (P/E)
- -0.2
- Beta (1Y)
- 1.00
- Revenue Growth
- -14.05%
- EPS Growth
- 55.98%
- Country
- US
- Employees
- 81
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
Lifeward Business Overview & Revenue Model
Company Description
Lifeward Ltd. is a healthcare technology company specializing in the creation, development, and commercialization of wearable robotic exoskeletons. These sophisticated devices are engineered to restore lower limb mobility for individuals living with...
How the Company Makes Money
Lifeward makes money primarily by selling and supporting medical devices and related mobility products. A core revenue stream is the sale of ReWalk exoskeleton systems to individual users and/or to institutional customers such as rehabilitation cente...
Lifeward Earnings Call Summary
Balanced mix of strategic, financial and operational positives (acquisitions, stronger cash position, ReWalk growth, cost reductions and reduced cash burn) offset by meaningful near-term operational headwinds (22% revenue decline, 800 bps gross margin compression, increased GAAP loss and manufacturing/supply chain disruptions). Management expects to resolve AlterG timing issues across Q2–Q3, sees a path to profitability and holds revenue expectation similar to prior year but retains execution risk during the transition.
Q1-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management did not raise formal 2026 guidance but reiterated they expect full‑year revenue to be similar to 2025, with the Q1 shortfall ($3.9M vs. $5.0M in Q1‑2025) to be largely made up across Q2–Q3 as AlterG backlog ships (potentially resolved by Q3); they highlighted ReWalk revenue up 11% YoY to $1.6M, gross margin down to 34.2% from 42.2% (~800 bps, 75–85% due to FX and tariffs and the rest from lower absorption), total operating expenses of $11.7M (including a ~$4.9M one‑time noncash R&D charge), adjusted Opex down 12% to $5.9M (from $6.8M), GAAP operating loss of $10.3M and unchanged adjusted operating loss of $4.6M, cash used in operations down 33% to $3.7M, and liquidity improved to $11.4M unrestricted cash (vs. $2.2M at YE‑2025) after a $10M convertible financing and ~ $6.5M cash from the Oratech acquisition, positioning the company for operational stabilization and a clearer path to profitability into late 2026/2027.
Lifeward Financial Statement Overview
Summary
Overall financials are weak, led by declining TTM revenue (~-3.5%) and extremely negative profitability (net loss ~$32.7M on ~$21.1M revenue; net margin ~-155%). Cash flow is a major concern with materially negative operating cash flow (~-$19.6M) and negative free cash flow, indicating ongoing cash burn. The main offset is relatively low debt (~$2.5M) and moderate debt-to-equity (~0.34x), but persistent losses are pressuring equity and financial flexibility.
Income Statement
18Very NegativeBalance Sheet
46NeutralCash Flow
22Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 21.05M | 22.03M | 25.66M | 13.85M | 5.51M | 5.97M |
| Gross Profit | 6.63M | 8.43M | 8.22M | 4.45M | 1.91M | 2.90M |
| EBITDA | -25.80M | -19.34M | -24.93M | -20.28M | -18.90M | -12.39M |
| Net Income | -32.71M | -19.91M | -28.94M | -22.13M | -19.57M | -12.74M |
Balance Sheet | ||||||
| Total Assets | 30.52M | 22.90M | 30.49M | 63.19M | 74.24M | 94.75M |
| Cash, Cash Equivalents and Short-Term Investments | 4.55M | 2.17M | 6.94M | 28.08M | 67.90M | 88.34M |
| Total Debt | 9.61M | 4.39M | 880.00K | 1.90M | 897.00K | 1.06M |
| Total Liabilities | 23.25M | 14.49M | 11.64M | 16.68M | 6.07M | 5.37M |
| Stockholders Equity | 7.27M | 8.41M | 18.85M | 46.51M | 68.17M | 89.38M |
Cash Flow | ||||||
| Free Cash Flow | -19.63M | -16.83M | -21.72M | -20.75M | -17.92M | -11.52M |
| Operating Cash Flow | -19.62M | -16.83M | -21.72M | -20.67M | -17.89M | -11.47M |
| Investing Cash Flow | -39.00K | -16.00K | 0 | -18.15M | -25.00K | -47.00K |
| Financing Cash Flow | 22.28M | 12.20M | 0 | -992.00K | -2.50M | 79.51M |
Lifeward Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LFWD, the sentiment is Negative. The current price of 2.95 is below the 20-day moving average (MA) of 5.26, below the 50-day MA of 6.01, and below the 200-day MA of 6.76, indicating a bearish trend. The MACD of -0.75 indicates Positive momentum. The RSI at 19.19 is Positive, neither overbought nor oversold. The STOCH value of 2.80 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LFWD.
Lifeward Risk Analysis
Lifeward disclosed 49 risk factors in its most recent earnings report. Lifeward reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksLifeward Peers Comparison
Overall Rating
NSPR51Neutral
NMTC49Neutral
CTSO47Neutral
TELA44Neutral
LFWD41Neutral
IRIX40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 51Neutral | $33.59M | -1.39 | -93.52% | ― | 35.75% | 29.98% | |
| 49Neutral | $6.15M | -0.74 | -126.45% | ― | -1.67% | 7.34% | |
| 47Neutral | $16.17M | -0.96 | -1339.98% | ― | 9.04% | -44.94% | |
| 44Neutral | $32.84M | -0.98 | 425.91% | ― | 1.46% | 15.79% | |
| 41Neutral | $8.37M | -0.19 | -382.80% | ― | -14.05% | 55.98% | |
| 40Underperform | $8.30M | -2.41 | -84.80% | ― | -2.77% | 36.12% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| LFWD | Lifeward Ltd. | 2.95 | -4.02 | -57.69% | |
| IRIX | Iridex | 0.47 | -0.45 | -49.35% | |
| NSPR | InspireMD Inc | 0.62 | -1.34 | -68.37% | |
| CTSO | Cytosorbents Corp | 5.13 | -11.45 | -69.06% | |
| NMTC | Neuroone Medical Technologies Corporation | 0.67 | -3.31 | -83.09% | |
| TELA | Tela Bio, Inc. | 0.73 | -0.41 | -36.32% |
Lifeward Corporate Events
Lifeward Shareholders Approve Key Proposals, Reject Compensation Policy
NeutralAt the October 30, 2026 annual and extraordinary general meeting, Lifeward shareholders representing 71.7% of outstanding ordinary shares constituted a quorum. Shareholders approved the re-election of Haggai Zamir and Avi Gabay, the election and comp...
Lifeward Appoints New Chief Financial Officer
PositiveOn October 26, 2026, Lifeward Ltd.’s board appointed seasoned finance executive Ronen Tsimerman as chief financial officer, principal financial officer and principal accounting officer, effective November 1, 2026. Tsimerman brings extensive experienc...
Lifeward Continues CFO Search After Candidate Withdraws
NegativeLifeward Ltd. had previously announced that Rami Aviram would become its chief financial officer, principal financial officer and principal accounting officer effective November 1, 2026, but on October 4, 2026 he informed the company he would not joi...
Lifeward Announces Interim CFO Leadership Transition Phase
NeutralOn September 30, 2026, Lifeward Ltd. completed the previously announced transition of its Chief Financial Officer role with the departure of Almog Adar as CFO, principal financial officer, and principal accounting officer. Effective October 1, 2026,...
Lifeward Sets Timeline for 2026 Shareholder Meeting
NeutralLifeward Ltd. has scheduled its 2026 Annual and Extraordinary General Meeting of Shareholders for October 30, 2026, marking a meeting date set more than 30 days after the anniversary of its 2025 annual general meeting. The board has outlined the time...
Lifeward Highlights Growth Strategy in New Investor Presentation
PositiveOn September 8, 2026, Lifeward posted a new investor presentation outlining its investment thesis and growth strategy, underscoring a commercial platform built around robotics, AI and reimbursement to restore motion and independence for patients with...
Lifeward Announces Major CEO and CFO Leadership Changes
NeutralLifeward Ltd. underwent significant leadership changes on August 31, 2026, when President and Chief Executive Officer Mark Grant departed from his executive roles and board seat under a separation agreement that ended future equity vesting and provid...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 18, 2026
